Dong, P., Wei, W., Peng, Y., Wang, D., Jiang, L., Zhang, Z., Huang, T., Zhong, X., Guo, S., Han, H., Xiong, W., Cai, X., Zhou, F. (2025). Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4526